75A50325C00004↗

Name: 75A50325C00004: Bulk Pharma - Group B (Asset Management) Acyclovir Sodium Solution, Doxycycline Inj., Meropenem, Sodium Chloride, Sterile Water
Creator: SpendQuery
License: https://www.usa.gov/government-works

Fresenius Kabi, LLC received this contract from Aspr/Orm-Sns, Office of Assistant Secretary for Preparedness and Response: $111.68M obligated so far for drugs and biologicals. It runs to 2030-03-13.

Key facts · data as of Oct 23, 2026

Recipient: Fresenius Kabi, LLC
Awarding agency: Office of Assistant Secretary for Preparedness and Response (Department of Health and Human Services)
Contracting office: Aspr/Orm-Sns (75A503)
Obligated to date: $111.68M
Potential value: $113.15M
Ends: 2030-03-13

Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 23, 2026.

Cite this page: SpendQuery, Award 75A50325C00004, data as of Oct 23, 2026, https://spendquery.com/award?id=CONT_AWD_75A50325C00004_7505_-NONE-_-NONE-

Fresenius Kabi, LLC: all federal awards · Department of Health and Human Services: spending · Aspr/Orm-Sns: what it buys

BULK PHARMA - GROUP B (ASSET MGMT) ACYCLOVIR SODIUM SOLUTION, DOXYCYCLINE INJ., MEROPENEM, SODIUM CHLORIDE, STERILE WATER

Definitive Contract · Office of Assistant Secretary for Preparedness and Response · to Fresenius Kabi, LLC (UEI C2TRNWNQKMD6) · data as of 2026-10-23

Obligated to date$111.68M3 actions

Current value$111.68Mwith options exercised

Potential value$113.15Mif every option is used

Period2025-03-14 → 2030-03-13current end date

What it is

Product or service: Drugs and Biologicals (PSC 6505)
Industry: Pharmaceutical Preparation Manufacturing (NAICS 325412)
Contracting office: Aspr/Orm-Sns (75A503)
Competition: Full and open competition · 5 offers received
Pricing: Firm fixed price
How it was bought: Standalone contract
Where the work is: Lake, IL · district IL-09

Obligations by fiscal year

FY2025$86.26M

FY2026$25.42M

SpendQuery holds FY2023 on; earlier years are on USAspending.gov.

Subcontractors: where the money went next

No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.

Every action

3 actions since 2025-03-12. Each is a modification or amendment with the money it added or took back.

Date	Modification	Kind	Amount	What the agency wrote
2026-08-31	P00002	Option exercised	$25.42M	EXERCISE OPTION FOR BULK PHARMA - GROUP B (ASSET MGMT) DOXYCYCLINE INJ., MEROPENEM, AND STERILE WATER
2025-09-11	P00001	Option exercised	$36.26M	BULK PHARMA - GROUP B (ASSET MGMT) ACYCLOVIR SODIUM SOLUTION, DOXYCYCLINE INJ., MEROPENEM, SODIUM CHLORIDE, STERILE WATER
2025-03-12	0		$50.00M	BULK PHARMA - GROUP B (ASSET MGMT) ACYCLOVIR SODIUM SOLUTION, DOXYCYCLINE INJ., MEROPENEM, SODIUM CHLORIDE, STERILE WATER

Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-23). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗

Putting the award page together from the records…